Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janelle Erickson

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 23, 2007
Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorderEduardo Dunayevich, Janelle Erickson, Louise Levine, et al.
Current Medical Research and Opinion|June 15, 2007
Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trialsChrister Allgulander, James Hartford, James Russell, et al.
The Journal of Clinical Endocrinology and Metabolism|October 23, 2009
Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placeboFrank L Greenway, Eduardo Dunayevich, Gary Tollefson, et al.
Depression and Anxiety|February 22, 2007
Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trialMoira Rynn, James Russell, Janelle Erickson, et al.
Lancet (London, England)|August 3, 2010
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialFrank L Greenway, Ken Fujioka, Raymond A Plodkowski, et al.
Primary Care Companion to the Journal of Clinical Psychiatry|July 4, 2007
Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physiciansHannu Koponen, Christer Allgulander, Janelle Erickson, et al.
Journal of the American Academy of Dermatology|September 23, 2014
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasisKenneth B Gordon, Craig L Leonardi, Mark Lebwohl, et al.
Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery|July 27, 2010
Path to bariatric nurse certification: the practice analysisNanette K Berger, Jamie J Carr, Janelle Erickson, et al.
The Journal of Clinical Psychiatry|May 4, 2007
Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studiesJean Endicott, James M Russell, Joel Raskin, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 19, 2008
Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trialJonathan R T Davidson, Hans-Ulrich Wittchen, Pierre-Michel Llorca, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 23, 2007
Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorderEduardo Dunayevich, Janelle Erickson, Louise Levine, et al.
Current Medical Research and Opinion|June 15, 2007
Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trialsChrister Allgulander, James Hartford, James Russell, et al.
The Journal of Clinical Endocrinology and Metabolism|October 23, 2009
Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placeboFrank L Greenway, Eduardo Dunayevich, Gary Tollefson, et al.
Depression and Anxiety|February 22, 2007
Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trialMoira Rynn, James Russell, Janelle Erickson, et al.
Lancet (London, England)|August 3, 2010
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialFrank L Greenway, Ken Fujioka, Raymond A Plodkowski, et al.
Primary Care Companion to the Journal of Clinical Psychiatry|July 4, 2007
Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physiciansHannu Koponen, Christer Allgulander, Janelle Erickson, et al.
Journal of the American Academy of Dermatology|September 23, 2014
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasisKenneth B Gordon, Craig L Leonardi, Mark Lebwohl, et al.
Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery|July 27, 2010
Path to bariatric nurse certification: the practice analysisNanette K Berger, Jamie J Carr, Janelle Erickson, et al.
The Journal of Clinical Psychiatry|May 4, 2007
Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studiesJean Endicott, James M Russell, Joel Raskin, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 19, 2008
Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trialJonathan R T Davidson, Hans-Ulrich Wittchen, Pierre-Michel Llorca, et al.
Pageof 2